Cargando…
Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer
Curative resection is the treatment of choice for potentially curable gastric cancer. Two major Western studies in the 1990s failed to show a benefit from D2 dissection. They showed extremely high postoperative mortality after D2 dissection, and were criticised for the potential inadequacy of the pr...
Autores principales: | Degiuli, M, Sasako, M, Ponti, A, Calvo, F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409745/ https://www.ncbi.nlm.nih.gov/pubmed/15150592 http://dx.doi.org/10.1038/sj.bjc.6601761 |
Ejemplares similares
-
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
por: Köhne, C-H, et al.
Publicado: (2003) -
Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
por: Fuse, Nozomu, et al.
Publicado: (2016) -
Risk of Dumping Syndrome after Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: Early Results of a Multicentre Prospective Study
por: Ramadan, M., et al.
Publicado: (2016) -
Ten‐year follow‐up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia
por: Kurokawa, Y., et al.
Publicado: (2015) -
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
por: Reardon, D A, et al.
Publicado: (2009)